2 results match your criteria: "Brigham and Women's Hospital Heart and Harvard Medical School[Affiliation]"
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
May 2022
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital Heart and Harvard Medical School, Boston, MA (R.H.M.F., E.L.G., S.A.M., D.L.B., M.S.S., S.D.W.).
Article Synopsis
- Dapagliflozin has shown to improve heart failure and kidney-related outcomes in patients with type 2 diabetes, particularly in those with or at high risk for cardiovascular disease, as demonstrated in the DECLARE-TIMI 58 trial.
- The trial involved 17,160 patients and assessed the medication's effects based on different levels of baseline systolic blood pressure (SBP) while monitoring both efficacy outcomes (like hospitalization for heart failure) and safety outcomes (like acute kidney injury).
- Results indicated that dapagliflozin decreased SBP and its benefits for heart and kidney health were consistent across various BP categories, with no serious safety issues related to the drug compared to placebo.
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation
August 2020
TIMI (Thrombolysis in Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital Heart and Harvard Medical School, Boston, MA (M.P.B., S.D.W., T.A.Z., D.L.B., E.L.G., M.S.S.).
Background: Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular complications. The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk for hospitalization for heart failure (HHF) and kidney events in patients with type 2 diabetes mellitus. An increased risk of amputation has been observed with canagliflozin in 1 previous trial.
View Article and Find Full Text PDF